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ABSTRACT 
BACKGROUND: Recent investigations consider actinic keratosis (AK) as an earliest 
visible pattern of squamous cell carcinoma (SCC). We have analyzed the expression 
of apoptosis-related proteins TP53, Bcl-2 and Bax in 30 atrophic and 30 hypertrophic 
AK.  
MATERIAL AND METHODS: Immunohistochemical analysis was performed 
following Microwave Streptavidin ImmunoPeroxidase protocol on DAKO 
TechMateTM Horizon automated immunostainer. Monoclonal antibody for TP53 and 
Bcl-2 and polyclonal antibody for Bax (DAKO, Denmark) were used.  
RESULTS: Expression of TP53 showed no significant differences between two 
analyzed groups (χ2-test, p=0.35636) whereas expression of Bcl-2 and Bax protein 
was significantly higher in atrophic compared to hypertrophic AK (χ2-test, p=0.01458 
and p=0.00358, respectively). Comparison of Bcl-2/Bax ratio in two analyzed AK 
showed significantly higher value in hypertrophic compared to atrophic AK (Mann-
Whitney U test, p=0.02272). Statistical analysis did not show any correlation between 
patient’s sex and age, localization and size of the lesion with expression of 
investigated oncoproteins (ANOVA, p>0.05).  
CONCLUSIONS: Our results may indicate higher resistance of keratinocytes on 
apoptotic stimuli in hypertrophic compared to atrophic AK. Thus, we suppose that 
keratinocytes in hypertrophic AK live longer and probably have higher propensity for 
additional mutations and conversion to overt SCC.  
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INTRODUCTION 
         Actinic keratosis (AK) is a common problem in the population, and one of the 
most common conditions treated by dermatologists. The main risk factors for the 
development of AK are increased sun exposure and increased susceptibility to sun 
exposure [1,2]. Working outdoors, having skin type I and/or a history of severe 
sunburns during childhood were found to be important factors in development of AK 
[3].  
         Processes of onset and progression of skin tumors and precanceroses such as AK 
are under control of various functional relationships between inactivated tumors 
suppressor genes and activated oncogenes [4-7]. The initial UV-induced damage in 
development of AK takes place in the DNA. The majorities of the UV-induced lesions 
in the DNA are repaired but if not, damaged keratinocytes undergo apoptosis. On this 
way apoptosis serves as a control mechanism, which prevents the propagation of 
keratinocytes with damaged DNA [8]. However, mutations may occur as a result of 
base mispairing of the cell and its DNA replicates before the DNA lesion is repaired. 
The genes involved in the repair and apoptotic process are also potential UV targets, 
especially tumor suppressor gene Tp53  [9]. It is well known that Tp53 gene plays a 
pivotal role in repair of UV-induced DNA damage and apoptosis. Consequently, Tp53 
alterations are early events in human UV-induced skin carcinogenesis [10]. They are 
present in more than 90% of squamous cell carcinomas (SCC) and are usually found 
in AK [11].   
         Except Tp53, other two genes bcl-2 and bax play major roles in the control of 
apoptosis. The bcl-2 gene belongs to a family of proto-oncogenes that are unrelated 
directly to cell proliferation, but participate in tumorigenesis by promoting cell 
survival via inhibition of apoptosis [12]. Oltvai et al. discovered the pro-apoptotic 
  
4 
4 
gene bax in 1993 and it is a first gene in apoptotic cascade initiated by Tp53 gene 
[13,14]. The bcl-2/bax ratio is considered to be a marker of a cell's susceptibility to 
apoptotic stimuli [13, 15-18).  
         AK was initially considered to be precancerous, because it presents with 
continuous, preserved basement membrane without invasion into the dermis [19]. 
However, AK shares many similarities with squamous cell carcinoma: causative 
factor (UV-light), clinical and pathological properties (i.e. localization, epidermal 
thickening, atypical keratinocytes) as well as molecular abnormalities (i. e. DNA 
aneuploidy, loss of heterozygosity) [20,21]. Thus, recent investigations consider AK 
as an earliest visible pattern of SCC, but there is still no generally accepted agreement 
about this new postulation [22-25]. 
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MATERIAL AND METHODS 
 
Patients 
         Our study group included consecutive specimens of 30 patients with atrophic 
type and 30 patients with hypertrophic type of AK who underwent surgery in the 
period from January 1st to December 31st, 2003. Clinical information about the 
patients (age, sex, lesion size and location) was obtained from the department charts. 
Specimens were fixed in 10% buffered formalin, embedded in paraffin, cut at 5 µm 
thickness and routinely stained with hematoxylin and eosin. The diagnosis of atrophic 
and hypertrophic type of AK was histologically confirmed in all cases and each 
specimen was re-evaluated by three pathologists (D.T., B.K. and H.Č.).  
 
Immunohistochemical analysis 
         Immunohistochemical determination of TP53, Bcl-2 and Bax proteins was 
performed following Microwave Streptavidin ImmunoPeroxidase (MSIP) protocol on 
DAKO TechMateTM Horizon automated immunostainer. We used monoclonal 
antibody DO-7 H7123 for TP53, monoclonal antibody 124 H7124 for Bcl-2 and 
polyclonal antibody 057 A3533 for Bax (purchased from DAKO, Copenhagen, 
Denmark). Dilution of antibodies for TP53 and Bcl-2 was “ready to use” 
(manufacturer diluted both antibodies 1:50). Antibody for Bax protein was diluted 
1:500. Positive control for TP53 staining was colon carcinoma tissue and for Bcl-2 
and Bax staining breast carcinoma tissue.  
         The positive cells were scored in whole lesion at X400 magnification. To 
evaluate the level of TP53, Bcl-2 and Bax protein expression, the percentages of 
positive-staining cells and the staining intensity were graded on a scale of 0 – 3. 
Staining percentage was labeled as: 0 = 0% positive cells; 1 = 1 – 10% positive cells; 
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2 = 11 – 25% positive cells; and 3 – 26% or more positive cells. Staining intensity 
was denoted as: 0 = no staining; 1 – weak staining; 2 – moderate staining; 3 – strong 
staining. For each sample, the staining percentage and staining intensity scores were 
multiplied to give staining index. Immunohistochemical staining index (ISI) was 
labeled as: 0 – zero; 1-3 = low; 4-6 = moderate; and 9 = high. 
 
Statistical analysis 
         Statistical analysis was performed using Mann-Whitney U test, χ2-test and 
ANOVA test. The level of significance was set at p < 0.05 in all cases. 
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RESULTS 
         The age range of the patients with atrophic type of AK was between 57 and 88 
years (median age 71.2). There were 15 females and 15 male patients (M/F = 1:1). 
Twenty-one (70.0%) lesions were localized on the face, 4 (13.3%) were located on the 
helix and 5 (17.7%) were on the neck. Lesions size varied between 0.2 and 1 cm 
(median size 0.8 cm). 
         The age range of the patients with hypertrophic type was between 59 and 81 
years (median 72.9 years), 18 patients were female and 12 patients were male (M/F = 
1.5:1). The most common location was the face (73.3%), subsequent location was 
helix (16.7%) and only 3 (10.0%) lesions were removed from neck. Size of lesions 
varied between 0.3 and 1 cm (median size 0.8 cm).  
         Statistical analysis revealed no statistically significant difference between two 
types of AK considering patient’s sex and age, localization and size (Mann-Whitney 
U test, p>0,05).  
         Immunohistochemical staining index for TP53, Bcl-2 and Bax protein in 
atrophic and hypertrophic AK is shown in Table 1. 
         Twenty-eight investigated atrophic AK (93.3%) were positive for TP53. Among 
them, minority (8, or 26.7%) had low ISI, 10 (33.3%) had moderate ISI and 10 
(33.3%) had high ISI. Twenty-nine of 30 hypertrophic AK (96.7%) were positive for 
TP53 and 1 (3.3%) was negative. Among positive hypertrophic AK, 13 (43.3%) had 
low ISI, 5 (16.7%) had moderate ISI and 11 (36.7%) had high ISI. In positive 
specimens most of the atypical epidermal keratinocytes were positive. The positive 
cells were diffusely spread in lesion (Figure 1A and 1B). 
         Immunohistochemical staining for TP53 showed no statistically significant 
difference between two analyzed groups (χ2-test, p=0.35636). 
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         IHC staining for Bcl-2 oncoprotein was detected in all investigated atrophic and 
hypertrophic AK (100%). Twelve (40.0%) atrophic and 23 (76.7%) hypertrophic AK 
had low ISI while 12 (40.0%) atrophic and 4 (13.3%) hypertrophic AK had moderate 
ISI. Only 6 (20.0%) atrophic and 3 (10.0%) hypertrophic AK had high ISI. In both 
types of AK the positive cells were predominantly located in the lower epidermis 
(Figure 1C and 1D). 
         Five (16.7%) atrophic and 15 (50.0%) hypertrophic AK were 
immunohistochemicaly negative for Bax protein. Fourteen (46.6%) atrophic and 13 
(43.3%) hypertrophic AK had low ISI. Moderate ISI had 11 (36.7%) atrophic and 
only 2 (6.7%) hypertrophic AK. None of analyzed actinic keratosis had high Bax ISI. 
In positive cases, immunoreactive cells were predominantly located in the basal and 
suprabasal layers of epidermis and positivity diminished toward surface of the lesion 
(Figure 1E and 1F). 
         Expression of Bcl-2 and Bax protein were statistically significantly higher in 
atrophic type compared to hypertrophic type AK (χ2-test, p=0.01458 and p=0.00358, 
respectively). 
         Comparison of Bcl-2/Bax ratio in two analyzed AK showed statistically 
significant higher value in hypertrophic type compared to atrophic type AK (Mann-
Whitney U test, p=0.02272) (Table 2). 
         Statistical analysis found no correlation between patient’s sex and age, 
localization and size of the lesion with ISI of investigated oncoproteins (ANOVA, 
p>0.05). 
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DISSCUSION  
         We analyzed the expression of apoptosis-related oncoproteins in two types of 
AK. The Tp53 tumor suppressor gene is essential in maintaining the genomic integrity 
of cells through its role in allowing repair of DNA damage or apoptosis. Nearly half 
of all human cancers contain mutation in Tp53 gene, although these mutations 
generally occur late in the tumorigenesis process [26]. Non-melanoma skin cancers 
are exception because of mutations that can be found in normal-appearing, chronically 
sun-exposed skin of patients with skin cancer and in premalignant lesions [27]. 
Studies have reported the presence of wild type Tp53 in acute ultra-violet exposure 
and both wild type and mutated Tp53 in AK and in normal skin with or without 
chronic sun exposure [28-30]. Several authors have suggested that the transient 
elevation of wild type Tp53 in normal epidermis following ultra-violet exposure is a 
reaction to damage to the genome, which arrests the cell cycle in G1 for repair 
purpose or, if that unsuccessful, induces apoptosis [31,32]. However, ultra-violet 
exposure may also cause specific mutations in the Tp53 gene that lead to its 
malfunction and expansion of mutated keratinocytes and progression to skin cancer 
[31]. Thus, TP53 immunopositivity should be analyzed with caution, because 
immunoreactivity may be related to overexpression or stabilization of wild type TP53 
or to the accumulation of mutant TP53 proteins. Conversely, negative 
immunoreactivity does not ultimately exclude presence of Tp53 truncated or missense 
mutations  [33].  
         Although there are many investigations of Tp53 expression in AK, there is no 
general agreement in the literature about the intensity of TP53-positive staining of 
AK. The results vary markedly, from 0% up to 100%, but different authors reported 
positivity in approximately 63% to 100% of analyzed AK specimens [34-39]. In the 
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largest series, Shimitzu reported immunohistochemical positivity of TP53 in 58 (85%) 
from 68 specimens [39]. Our results of prominent TP53 immunopositivity in AK are 
consistent with reports in the literature [34-39]. In our study, statistical analysis found 
no significant differences between the expressions of Tp53 protein in two investigated 
AK types. We did not determine whether the immunopositivity was a related to 
mutated TP53 or accumulation of the wild type protein, but both possibilities are 
feasible and may even coexist. The positivity of TP53 protein in both types of 
analyzed AK was located in nucleus and diffusely dispersed through lesions, which is 
consistent with literature data [34-39].  
          Bcl-2 family member proteins, including the anti-apoptotic Bcl-2 protein and 
the pro-apoptotic Bax protein, are important regulators of apoptosis [39].  The 
relationship between Bcl-2 and Bax and their capacity for heterodimerization are 
thought to determine the apoptotic status of the cell [13]. Thus, altered expression of 
these genes contributes to neoplastic cell expansion by prolonging cell survival  [15-
18].  
         The anti-apoptotic Bcl-2 oncoprotein is normally expressed in basal 
keratinocytes and has been shown to be deregulated in skin cancers [41]. Several 
authors investigated Bcl-2 expression in AK, but there was no general agreement in 
the literature about the intensity of Bcl-2 positivity [36,37,42-46]. The majority of 
these investigations have been performed on relatively small number of AK 
specimens (up to 10) [42-45] except three recent investigations, two performed by 
Stanimirović et al. [36,37] and one performed by Feinmesser et al. [46]. Feinmesser 
analyzed Bcl-2 expression in 20 AK and revealed positivity in only 35% of cases [46]. 
In our study, all investigated AK showed Bcl-2 expression but the majority was 
weakly positive, and only 41.7% of investigated AK had stronger immunoreaction 
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than unaffected perilesional skin which is consistent with results in the literature 
[36,37,46]. Comparison of Bcl-2 expression in atrophic and hypertrophic AK revealed 
statistically significant stronger expression in atrophic type. The strongest positivity of 
Bcl-2 protein in both types of analyzed AK was located in cytoplasm of basally 
located keratinocytes. In lesions with the most intensive immunoreaction, positive 
keratinocytes were also observed in the upper epidermal layers. Nakagawa and Tucci 
reported same pattern of Bcl-2 immunopositivity in AK [42,45]. 
         The pro-apoptotic Bax protein is normally expressed in the suprabasal cells in 
the normal epidermis [47,48]. Bax opposes Bcl-2 function and enhances susceptibility 
of cell to undergo apoptosis [13]. Some studies have reported that is also related to 
keratinocyte differentiation [16]. However, other studies found that apoptosis and 
terminal differentiation of keratinocytes are distinct processes [49].  
         Only few authors paid attention to the expression of Bax protein in AK [37,45]. 
The first investigation was performed by Einspahr et al., which compared expression 
of Bax protein in 13 SCC, 16 AK and 14 normal-appearing skin samples, and 
concluded that Bax protein was significantly increased in SCC compared to AK. 
However, they did not specify how many samples of AK were 
immunohistochemically positive and which type of AK investigated [38]. In a recent 
study by Feinmesser and his group Bax immunopositivity was found in 18 (90%) 
from 20 investigated AK but only in 2 (11%) of 18 cases AK immunopositvity was 
strong [46]. They also did not specify which type of AK was used in investigation. In 
our study immunohistochemical staining showed that Bax expression was present in 
40 (66.7%) AK specimens. In the atrophic type AK Bax expression was observed in 
25 (83.3%) specimens, whereas only 15 (50%) hypertrophic AK showed 
immunohistochemical positivity of Bax protein. ISI was predominantly low in both 
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investigated type AK. Statistical analysis revealed significantly stronger 
immunoreactions on Bax protein in atrophic type compared to hypertrophic type AK. 
In positive cases immunoreactions was located in the cytoplasm of basally and 
suprabasally located keratinocytes and decreased gradually toward the more 
superficial layers, which is consistent with literature data [46].  
         However, simple determination and comparison of Bcl-2 and Bax 
immunopositivity is not sufficient for better characterization and understanding of 
apoptotic processes in two investigated types of AK. Some investigations revealed 
that cell susceptibility on apoptotic stimuli was directly dependent on Bcl-2/Bax ratio 
in cell cytoplasm [15,17,18]. Raisova at al. in their study on melanoma cell culture 
showed that increased bcl-2/bax ratio characterized cells resistant on apoptotic stimuli 
[15]. Cho and his group confirmed higher resistance on apoptosis induced by ultra-
violet radiation in keratinocytes from bax (-/-) mice, which also had higher incidence 
of several tumors compared to control [17]. In a recent study Adhami, contrary to 
Raisova, showed that decreased bcl-2/bax ratio characterized cells that initiated 
apoptotic process [18]. In our investigation, Bcl-2/Bax ratio was statistically 
significantly higher in hypertrophic compared to atrophic type of AK.  
         Our results may indicate higher resistance of keratinocytes on apoptotic stimuli 
in hypertrophic compared to atrophic AK. Thus, we suppose that keratinocytes in 
hypertrophic AK live longer and probably have higher propensity for additional 
mutations, which may lead to malignant transformation and conversion to overt SCC. 
Furthermore, we propose a hypothesis that hypertrophic AK is the earliest visible 
pattern of SCC, whereas atrophic type is still precancerosis but further studies at the 
molecular level are needed to clarify this issue.  
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Table 1 Immunohistochemical staining index (ISI) for TP53, Bcl-2 and Bax protein in 
atrophic and hypertrophic actinic keratosis (AK). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATROF ATROPHIC AK HYPERTROPHIC AK
29 (96.7%) 30 (100%) 15 (50.0%)
11 (36.7%) 3 (10.0%) 0 (0%)
5 (16.7%) 4 (13.3%) 2 (6.7%)
13 (43.3%) 23 (76.7%) 13 (43.3%)
Tp53 Bcl-2 Bax
1 (3.3%) 0 (0%) 15 (50.0%)
TOTAL 
POSITIVE 28 (93.3%) 30 (100%) 25 (83.3%)
ISI 3 10 (33.3%) 6 (20.0%) 0 (0%)
ISI 2 10 (33.3%) 12 (40.0%) 11 (36.7%)
ISI 1 8 (26.7%) 12 (40.0%) 14 (46.6%)
Tp53 Bcl-2 Bax
ISI 0 2 (6.7%) 0 (0%) 5 (16.7%)
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Table 2 Comparison of Bcl-2/Bax ratio in two analyzed AK by Mann-Whitney U Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p=0.022726
ATROPHIC AK HYPERTROPHIC AK
MANN-WHITNEY 
U TEST
Mean 0.694 0.455
Median 0.500 0.083
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Figure 1 Microphotographs of immunohistochemical staining for TP53 (A), Bcl-2 (C) 
and Bax  (E) protein in atrophic type of actinic keratosis and for TP53 (B), Bcl-2 (D) 
and Bax (F) protein in hypertrophic type of actinic keratosis (All microphotographs 
were made under high magnification, 400X). 
    
    
    
